Refine your search

Clear

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

NASH is associated with increased risk of mortality. Currently, there are few treatment options. Therefore, there is a need for an effective and safe medication treatment options. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), can address certain aspects of NASH and is therefore considered a strong candidate for the treatment of NASH.
Gloriany Rivas at stinelaboratory@pennstatehealth.psu.edu or 717-531-0003, ext=320223
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04822181
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Biopsy consistent with NASH and presence of fibrosis stage 2 or 3
able to provide consent
18 years or older
Exclusion Criteria:
previous participation in this trial
known/suspected allergic reaction to study drug
pregnancy
cirrhosis
hepatocellular carcinoma
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA